Attorney's Docket No. 007157/270549 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Snyder *et al.*	Confirmation No.:	4831
Appl. No.:	10/690,462	Group Art Unit:	1614
Filed:	October 21, 2003	Examiner:	(*not yet assigned*)
For:	CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES		

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

May 17, 2004

INFORMATION DISCLOSURE STATEMENT
CITATION UNDER 37 C.F.R. § 1.97

Attached is a list of documents on Form PTO-1449. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

All documents were supplied in, or cited by the Office during prosecution of, parent Application No. 09/729,662 filed December 4, 2000. Since the benefit of this application was claimed under 35 U.S.C. 120, no copies need to be furnished in accordance with 37 C.F.R. 1.98(d); however, copies will be furnished on request.

Respectfully submitted,

Christopher M. Humphrey
Registration No. 43,683

Customer No. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

"Express Mail" mailing label number: EV387076958US
Date of Deposit: May 17, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Tracey S. Wright

Substitute for form 1449/PTO (Revised 04/2003)	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*	Application Number	10/690,462
	Filing Date	October 21, 2003
	First Named Inventor	Snyder
	Group Art Unit	1614
	Examiner Name	*(not yet assigned)*
Sheet 1 of 3	Attorney Docket Number	007157/270549

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	US-3,114,775	12-17-1963	Hughes *et al.*	
	2	US-3,911,129	10-07-1975	Krapcho *et al.*	
	3	US-4,127,667	11-28-1978	Rovnyak	
	4	US-4,415,621	11-15-1983	Specht *et al.*	
	5	US-4,755,450	07-05-1988	Sanders *et al.*	
	6	US-4,987,057	01-22-1991	Kaji *et al.*	
	7	US-5,700,804	12-23-1997	Collins *et al.*	
	8	US-5,811,218	09-22-1998	Kaji *et al.*	
	9	US-5,852,018	12-22-1998	Bryans *et al.*	
	10	US-6,022,597	02-08-2000	Yan *et al.*	
	11	US-2002/0006966 A1	01-17-2002	Arbiser	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	12	JP – 03/44643	02-26-1991	Hioki *et al.*		
	13	WO – 01/46110	06-28-2001	The University of Georgia Research Foundation, Inc. *et al.*		

Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. RTA01/2144500v1

Substitute for form 1449/PTO (Revised 04/2003)	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*	Application Number	10/690,462
	Filing Date	October 21, 2003
	First Named Inventor	Snyder
	Group Art Unit	1614
	Examiner Name	*(not yet assigned)*
Sheet 2 of 3	Attorney Docket Number	007157/270549

OTHER DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	14	ARTICO, *et al.*, "Geometrically and Conformationally Restrained Cinnamoyl Compounds as Inhibitors of HIV-1 Integrase: Synthesis, Biological Evaluation, and Molecular Modeling," *J. Med. Chem.*, 1998, pp. 3948-3960, Vol. 41, No. 21.	
	15	CREMLYN *et al.*, "The Synthesis and Chlorosulfonation of Some Diarylidene and Heteroarylidene Ketones with Varying Alicyclic Ring Size", *Phosphorus, Sulfur, and Silicon*, 1995, pp. 205-217, Vol. 107.	
	16	DINKOVA-KOSTOVA, *et al.*, "Chemoprotective Properties of Phenylpropenoids, Bis(benzylidene)cycloalkanones, and Related Michael Reaction Acceptors: Correlation of Potencies as Phase 2 Enzyme Inducers and Radical Scavengers," *J. Med. Chem.*, 1998, pp.5287-5296, Vol. 41, No. 26.	
	17	EL-SUBBAGH, *et al.*, "Synthesis and Biological Evaluation of Certain α,β-Unsaturated Ketones and Their Corresponding Fused Pyridines as Antiviral and Cytotoxic Agents," *J. Med. Chem.*, 2000, pp.2915-2921, Vol. 43, No. 15.	
	18	FUJISAKI, *et al.*, JP 62225562, 1988 (CA 108:77360).	
	19	GUTKOWSKA, *et al.*, *Acta Poloniae Pharmaceutica*, 1985, pp. 437-441, Vol. 42, No. 5 (CA 107:115819).	
	20	GUTKOWSKA, *et al.*, *Acta Poloniae Pharmaceutica*, 1989, pp. 212-218, Vol. 46, No. 3 (CA 112:216649).	
	21	HAMMAM, *et al.*, "Synthesis and Anti-Cancer Activity of Pyridine and Thiazolopyrimidine Derivatives Using 1-Ethylpiperidone as a Synthon," *Indian J. Chem.*, 2001, pp. 213-221, Vol. 40B.	
	22	KEINAN, *et al.*, *J. Org. Chem.*, 1983, pp. 5302-5309, Vol. 48, No. 26.	
	23	LI, *et al.*, "Samarium (III) Iodide Promoted Preparation of α,α' – bis(substituted benzylidene) cyclohexanones from Benzaldehydes and Cyclohexanone," *J. Chem, Research (S)*, 2000, pp. 580-581.	
	24	MAHFOUZ, *et al.*, "Synthese mehrfach oxigenierter 2-Hydroxyxanthone," *Arch. Pharm. (Weinheim)*, 1990, pp. 163-169, Vol. 323.	
	25	NAKANO, *et al.*, "A Convenient Synthesis of α,α' – Bis(substitutedbenzylidene)cycloalkanones," *Chemistry Letters*, 1993, pp. 2157-2158.	

Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. RTA01/2144500v1

Substitute for form 1449/PTO (Revised 04/2003)				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/690,462
				Filing Date	October 21, 2003
				First Named Inventor	Snyder
				Group Art Unit	1614
				Examiner Name	*(not yet assigned)*
Sheet	3	of	3	Attorney Docket Number	007157/270549

OTHER DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) , volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	26	OJIMA, *et al.*, *Bull. Chem. Soc. Jpn.*, 1977, pp. 1522-1526, Vol. 50, No. 6 (CA 87:20055).	
	27	PIVNENKO, *et al.*, *Zh. Org. Khim*, 1972, pp. 1096-1102, Vol. 42, No. 5 (CA 84:513251).	
	28	PIVNENKO, *et al.*, *Zh. Org. Khim*, 1975, pp. 2527-2533, Vol. 11, No. 12 (CA 84:73234).	
	29	SHOPPEE, *et al.*, *J. Chem. Soc. Perkin Trans I*, 1977, pp. 1028-1030, Vol. 9 (CA 87:102029).	
	30	SUN, *et al.*, "Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases," *J. Med. Chem.*, 1999, pp. 5120-5130, Vol. 42, No. 25.	
	31	SUN, *et al.*, "Identification of Substituted 3-[(4,5,6,7-Tetrahydro-1*H*-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as Growth Factor Receptor Inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ Tyrosine Kinases," *J. Med. Chem.*, 2000, pp. 2655-2663, Vol. 43, No. 14.	
	32	SUN, *et al.*, "Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases," *J. Med. Chem.*, 1998, pp. 2588-2603, Vol. 41, No. 14.	
	33	TEUSCHER, " Potentiell antiangiogene Substanzen aus der Gruppe der α, α'-Bis(amidinobenzyl)cycloalkanon-Derivate und α-(Arylsulfonylamino)-ω-phenylcarbonsäure-4-amidinoanilide," *Pharmazie*, 1987, pp. 109-110, Vol.42, H.2.	
	34	THALOOR, *et al.*, " Inhibition of Angiogenic Differentiation of Human Umbilical Vein Endothelial Cells by Curcumin," *Cell Growth & Differentiation*, 1998, pp. 305-312, Vol. 9.	
	35	VIETH, *et al.*, "DoMCoSAR: A Novel Approach for Establishing the Docking Mode That Is Consistent with the Structure-Activity Relationship. Application to HIV-1 Protease Inhibitors and VEGF Receptor Tyrosine Kinase Inhibitors", *J. Med. Chem.*, 2000, pp. 3020-3032, Vol. 43, No. 16.	
	36	WIEMER *et al.*, "Vidalols A and B, New Anti-Inflammatory Bromophenols from the Caribbean Marine Red Alga *Vidalia obtusaloba*," *Experientia*, 1991, pp. 851-853, Vol. 47.	
	37	ZHENG, *et al.*, *Zhongguo Yiyao Gonye Zazhi*, 1997, p. 230231, Vol. 28, No. 5 (CA 115:102878).	

Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. RTA01/2144500v1